Adverse effects of advanced glycation end products on embryonal development

被引:0
|
作者
Hao, Lin [1 ,3 ]
Noguchi, Soichi [1 ]
Kamada, Yasuhiko [1 ]
Sasaki, Aiko [1 ,3 ]
Matsuda, Miwa [1 ,3 ]
Shimizu, Keiko [1 ,3 ]
Hiramatsu, Yuji [1 ,3 ]
Nakatsuka, Mikiya [1 ,2 ]
机构
[1] Okayama Univ Hosp, Dept Obstet & Gynecol, Okayama 7008558, Japan
[2] Okayama Univ, Grad Sch Hlth Sci, Okayama 7008558, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Obstet & Gynecol, Okayama 7008558, Japan
关键词
advanced glycation end products; blastocyst; embryo; in vitro fertilization; N-acetyl-L-cysteine;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We studied the effects of advanced glycation end products (AGEs), which are known to accumulate in patients with diabetes, autoimmune diseases, or those who smoke, on embryonal development. Pronuclear (PN) embryos were obtained by flushing the fallopian tubes of rats after superovulation and mating. The cleavage rate and blastocyst yield were evaluated at 24, 72, 96, and 120 h of culture. Glyoxal, an AGE-forming aldehyde, suppressed embryonal development at every stage from PN to blastocyst in a concentration-dependent manner. The cleavage rate of the embryo was also significantly decreased by treatment with glyoxal at concentrations of 1 mM or higher. The blastocyst yield was significantly decreased by treatment with glyoxal at concentrations of 0.5 mM or higher. N-acetyl-L-cysteine (L-NAC) at I mM significantly suppressed the glyoxal-induced embryonal toxicity. BSA-AGEs at 5 mu g/ml or higher concentration significantly reduced the cleavage rate and blastocyst yield compared to those for BSA-treated embryos. L-NAC at I mM significantly suppressed BSA-AGE-induced embryonal toxicity. Because AGEs are embryo-toxic, AGE contamination may influence the pregnancy rate of in vitro fertilization and embryo transfer. AGEs, which are increased in women under pathological conditions, may also be involved in their infertility.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 50 条
  • [41] Advanced glycation end products in AA amyloidosis
    Röcken, C
    Schwan, M
    Mansfeld, S
    Raynes, J
    Stix, B
    Saeger, W
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2001, 8 : 46 - 47
  • [42] Advanced Glycation End Products in Health and Disease
    Reddy, V. Prakash
    Aryal, Puspa
    Darkwah, Emmanuel K.
    MICROORGANISMS, 2022, 10 (09)
  • [43] Advanced glycation end products: Detection and reversal
    Al-Abed, Y
    Kapurniotu, A
    Bucala, R
    AMYLOID, PRIONS, AND OTHER PROTEIN AGGREGATES, 1999, 309 : 152 - 172
  • [44] Advanced glycation end products and diabetic retinopathy
    Ross Milne
    Seymour Brownstein
    Amino Acids, 2013, 44 : 1397 - 1407
  • [45] Advanced glycation end products, diabetes and ageing
    Nass, N.
    Bartling, B.
    Santos, A. Navarrete
    Scheubel, R. J.
    Boergermann, J.
    Silber, R. E.
    Simm, A.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2007, 40 (05): : 349 - 356
  • [46] Advanced Glycation End Products and Diabetic Retinopathy
    Chen, M.
    Curtis, T. M.
    Stitt, A. W.
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (26) : 3234 - 3240
  • [47] Advanced glycation end products, diabetes, and the brain
    Coker, Laura H.
    Wagenknecht, Lynne E.
    NEUROLOGY, 2011, 77 (14) : 1326 - 1327
  • [48] ADVANCED GLYCATION END PRODUCTS IN SYSTEMIC SCLEROSIS
    Triginer, L.
    Tio, L.
    Carrion, I.
    Guillen-Del-Castillo, A.
    Ribes, A.
    Valencia Muntala, L.
    Monfort, J.
    Salman, T. C.
    Pros, A.
    Narvaez, J.
    Simeon Aznar, C. P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1655 - 1656
  • [49] Advanced glycation end products, dementia, and diabetes
    Lovestone, Simon
    Smith, Ulf
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (13) : 4743 - 4744
  • [50] Role of dietary advanced glycation end products
    Clifton, Peter
    Keogh, Jennifer
    CURRENT OPINION IN LIPIDOLOGY, 2017, 28 (06) : 514 - 515